Background
For people living with glioblastoma (GBM), finding out that their tumour has returned can bring difficult decisions about what happens next. Treatment options may be limited, and the possibility of further surgery or treatments needs to be considered alongside quality of life, independence and time spent with family and loved ones.
brainstrust are delighted to be working with an international team of researchers working on a project investigating a new approach to treating recurrent glioblastoma, combining personalised drug selection with treatment delivered directly to the area where the tumour has been removed.
The researchers hope to analyse the genetic characteristics of a person’s tumour during surgery to identify combinations of drugs that might be effective against it. These drugs would then be incorporated into a specially developed gel, placed into the space left after surgery, with the aim of reaching cancer cells that may remain in the surrounding tissue.
This approach is still being investigated in the laboratory. Through PRIME, we’re working with the research team to bring patients and caregivers into these early conversations, exploring how the proposed approach might be viewed by people affected by glioblastoma and what researchers should consider when developing a future clinical trial.
Who can get involved?
We are looking for:
- People living with glioblastoma, including those who have experienced recurrence
- Caregivers, family members and loved ones of someone affected by glioblastoma
- Bereaved family members and caregivers of someone who had glioblastoma
What will you do?
Join brainstrust for a small, relaxed online conversation about this developing treatment approach and what it might mean for people living with glioblastoma.
We’ll introduce the research in accessible terms and explore your thoughts about the possibility of selecting drugs based on an individual tumour and delivering them directly into the brain during surgery.
We’re particularly interested in understanding how people approach decisions about further treatment following recurrence, what questions or concerns this approach raises, and how the potential benefits and uncertainties might be weighed against the practical and personal impact of treatment.
We’ll also explore what people would want to know before considering participation in a future clinical trial, what might make taking part more or less manageable, and which outcomes would matter most to them.
There are no right or wrong answers. We’re interested in your experiences, questions and perspectives, including where these might challenge the researchers’ assumptions about what is important.
Please note that these workshops will take place online via Zoom. You’ll receive joining details after registering.
